Revenue Misses Estimates, EPS Beats in Resmed's Mixed Q3
summarizeSummary
Resmed reported mixed third-quarter fiscal year 2026 results, with revenue rising 11% to $1.4 billion but missing analyst expectations of $1.42 billion. Despite the top-line miss, adjusted EPS increased 21% to $2.86, surpassing the $2.80 consensus estimate. The company also saw a 290 basis point improvement in gross margin, driven by component cost improvements and operational efficiencies, and returned $262 million to shareholders. While strong product demand and profitability are positive, the revenue miss could be a concern for investors, especially as the stock trades near its 52-week low. Traders will be watching how the market reacts to the mixed performance and the absence of specific forward guidance.
At the time of this announcement, RMD was trading at $208.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.1B. The 52-week trading range was $210.60 to $293.81. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.